Quarterly ResultMay 7, 2026, 04:36 PM
Tectonic Therapeutic Q1 Net Loss $25.2M; TX45 & TX2100 Trials Advance
AI Summary
Tectonic Therapeutic reported a net loss of $25.2 million for Q1 2026, an increase from $15.9 million in Q1 2025. The company provided significant updates on its clinical pipeline, including nearing completion of TX45 APEX Phase 2 enrollment and advancing TX2100 into Phase 1a for HHT. Additionally, the TX45 ALPINE Phase 2 trial for PH-ILD was initiated, and leadership was strengthened with new board appointments. Tectonic anticipates its $236.9 million cash and cash equivalents will provide a runway into Q4 2028.
Key Highlights
- Q1 2026 net loss was $25.2 million, compared to $15.9 million in Q1 2025.
- Cash and cash equivalents totaled $236.9 million as of March 31, 2026.
- Cash runway expected to extend into Q4 2028.
- TX45 APEX Phase 2 enrollment nearing completion; results late Q4 2026/early Q1 2027.
- TX2100 Phase 1a trial initiated for HHT; topline results expected end of Q3 2026.
- TX45 ALPINE Phase 2 trial initiated for PH-ILD.
- François Nader, M.D., appointed Chair of the Board.
- Jessica Chutter appointed independent board director.
Price Impact
More from TECX